Amgen (AMGN) Stock Price & Analysis

AMGN$465.67-1.39 -0.30%
Drug Manufacturers - GeneralMega CapHigh Quality
Compare
Market cap$251.89BEnterprise value$299.50BRevenue (TTM)$38.93BMarket positionTop 5%

Score

58
Neutral
Value
39
Quality
76
Growth
58

AI Analysis

Snapshot

Amgen looks like a quality compounder first — Quality 76/100 and an overall 58/100. Under the hood: P/E 27.5, rich vs its own history, plus revenue compounding ~12% annually over recent years.

Price History

Bullish (65+)Neutral (45–64)Bearish (<45)

Score Breakdown

Market percentile scores loading…

Value

39
PE Ratio (F)–
PEG Ratio–
Free Cashflow Yield %–
EV/EBITDA Ratio–
Discount vs All Time Peak–
Discount vs 1Y Peak–

Growth

58
Earnings Forecast–
Last 3M Earnings Growth %–
12M Revenue Growth %–
12M Earnings Growth %–
5 YR CAGR % Earnings–
Analyst Price Forecast–

Quality

76
FCF Margin %–
Net Debt / EBITDA–
Operating Margin %–
Operating Margin Growth %–
ROCE %–
Current Ratio–

Financial Summary

Amgen Inc. (AMGN) last printed $465.67. Equity value is $251.89B. Trailing earnings multiple 26.82. The revenue row is reported history. Targets and ratings are on the forecast page.

Financials

2016201720182019202020212022202320242025
$22.99B$22.85B$23.75B$23.36B$25.42B$25.98B$26.32B$28.19B$33.42B$36.74B

About

Amgen Inc., established in 1980 and headquartered in Thousand Oaks, California, is a global biotechnology leader focused on discovering, developing, manufacturing, and delivering groundbreaking human medicines. The company's scientific endeavors span several critical therapeutic categories, including inflammatory conditions, oncology and hematology, bone health, cardiovascular diseases, nephrology, and neuroscience. Its extensive portfolio features a range of significant pharmaceutical products. Notable examples include Enbrel, prescribed for conditions like plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Neulasta, which helps cancer patients by reducing the risk of infection linked to a low white blood cell count; Prolia, utilized in postmenopausal women to combat osteoporosis; and Xgeva, designed to prevent skeletal-related complications. Otezla offers relief for adult patients suffering from plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease. Aranesp addresses anemia and low red blood cell counts, while KYPROLIS is employed to treat patients with relapsed or refractory multiple myeloma. Furthermore, Repatha plays a vital role in lowering the incidence of major cardiovascular events such as myocardial infarction, stroke, and coronary revascularization. Amgen's comprehensive product lineup also encompasses Nplate, Vectibix, MVASI, Parsabiv, EPOGEN, KANJINTI, BLINCYTO, Aimovig, EVENITY, AMGEVITATM, Sensipar/Mimpara, NEUPOGEN, IMLYGIC, Corlanor, and AVSOLA. The company distributes its therapies worldwide, primarily serving healthcare providers, including physicians and their clinics, dialysis centers, hospitals, and pharmacies. Distribution is facilitated through pharmaceutical wholesale distributors, complemented by direct-to-consumer channels. Amgen actively engages in strategic collaborations. It has partnered with entities such as Novartis Pharma AG, UCB, Bayer HealthCare LLC, BeiGene, Ltd., Eli Lilly and Company, Datos Health, and Verastem, Inc., to jointly assess VS-6766 when combined with lumakrastm (Sotorasib) in patients with KRAS G12C-mutant non-small cell lung cancer. Another key alliance involves Kyowa Kirin Co., Ltd., for the co-development and commercialization of KHK4083, a Phase 3-ready anti-OX40 fully human monoclonal antibody targeting atopic dermatitis and other autoimmune conditions. Additionally, Amgen maintains research and development partnerships with Neumora Therapeutics, Inc. and Plexium, Inc.

Amgen (AMGN) Stock Price & Analysis

AMGN price $465.67 -1.39 -0.30%

Ticker
AMGN
Price
$465.67
Change
-1.39 -0.30%
Market cap
$251.89B
P/E
26.82
Forward P/E
19.14
Dividend yield
2.08%
Beta
0.42
Sector
Healthcare
Industry
Drug Manufacturers - General
Stocklytics score
58
Value
39
Quality
76
Growth
58

Stocklytics score rationale: value 39, quality 76, growth 58.

AI Score 75. Amgen Inc. has a strong market cap of $258.68 billion and a solid net profit margin of 24.1%, indicating good profitability

Insights · Dividends · Forecast · Financials · Learn

Stocklytics home · Screener